Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Central Nervous System
- Cannabis
- Delivery
- Drug Discovery
- Disease
- Therapeutic
- Biotechnology
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 305651
License Grant
The agreement is for marketing rights in the United States to ET-105. Pursuant to the terms of the License Agreement, Licensee will be responsible for marketing activities and Licensor will be responsible for development, manufacturing, and regulatory activities related to obtaining regulatory approval.
License Property
ET-105 or Lamotrigine for Oral Suspension, is an innovative formulation of lamotrigine to be delivered to patients as an oral suspension. ET-105 is a product candidate for use as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older.
Licensor is a pharmaceutical company with a focus in CNS (central nervous system), Dermatology, and Pediatrics.
Field of Use
The NDA has been submitted to the FDA and is under review for the treatment of partial on-set seizures, primary generalized tonic-clonic seizures, and seizures of Lennox-Gastaut syndrome in patients two year of age and older.
IPSCIO Record ID: 377097
License Grant
Licensee entered into a collaboration with Licensor of the United Kingdom for the exclusive worldwide license to develop and commercialize an investigational formulation delivered via the nasal route to enhance pharmaceutical-grade cannabidiol (CBD) transport to the brain to potentially treat seizures associated with tuberous sclerosis complex (TSC),
License Property
VRP324, the first investigational formulation delivered via the nasal route to enhance CBD transport to the brain. VRP324 uses a preassembled device and cartridge to propel the CBD powder formulation into the nose to the brain via the olfactory nerve/bulb.
VRP324 is a drug product candidate based on nanotechnology which enables the delivery of CBD into the brain via intranasal delivery for the management of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older, as well as patients one year of age and older who experience seizures associated with Lennox-Gastaut syndrome ( LGS) or Dravet syndrome. VRP324 is manufactured using high pressure homogenization and spray drying. In animal studies, the MET nanoparticles are well-tolerated via the nasal route at the dose administered.
Field of Use
The rights are to use Licensor’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children.
Field of use is for the treatment of seizures associated with tuberous sclerosis complex (TSC) Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older.
Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment.
Tuberous sclerosis complex (TSC) is a hereditary condition associated with changes in the skin, brain, kidney, and heart. Seizures are a frequent complication, and some people with TSC have learning disabilities. Skin changes are the most noticeable sign of TSC and appear in nearly all people with the condition.
IPSCIO Record ID: 215874
License Grant
Licensee has in-licensed the rights to use the Licensor patents with drugs that like carbamazepine are voltage-gated sodium channel blockers in North America.
License Property
Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.
Field of Use
The license field includes Sodium-voltage gated channels inhibitors and blockers for the treatment of epilepsy, neuropathic pain, and bipolar disorder.
IPSCIO Record ID: 25926
License Grant
Licensor entered into a License Agreement with a privately-held company granting it an exclusive worldwide license for the development and commercialization of Captisol-enabledâ„¢ Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate. A successful Phase 1 clinical trial of Captisol-enabled Topiramate Injection has already been completed, and licensee has announced that it intends to commence a Phase II clinical trial during 2014.
License Property
The Captisol-enabled Topiramate Injection formulation is designed to provide an intravenous or intramuscular option for hospitalized epilepsy patients unable to use oral topiramate. Captisol® is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.
IPSCIO Record ID: 303746
License Grant
The parties entered into an exclusive worldwide license agreement to develop and commercialize V158866, a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.
License Property
V158866 is for post-traumatic stress disorder and other central nervous system diseases. V158866 is a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
Field of Use
Licensee will utilize the inhibitor, V158866, for post-traumatic stress disorder and other central nervous system diseases.
Licensee is a biopharmaceutical company committed to developing treatments for psychiatric disorders.
IPSCIO Record ID: 369272
License Grant
University hereby grants to Licensee the world-wide right and license to the Patent Rights set forth to the full end of the term of each patent included therein unless sooner terminated as hereinafter provided. This grant is expressly subject to the rights of the U.S. Government, if any.
In order to establish a period of exclusivity for Licensee, University hereby agrees that it shall not grant any other license to make, have made, use, lease and sell the Patent Rights during the period of time commencing with the Effective Date of this Agreement and terminating with the full end of the term of this Agreement, unless sooner terminated as hereinafter provided.
Licensee shall have the right to sublicense worldwide any of the rights, privileges and license granted hereunder.
License Property
Patent Rights' shall mean
5,616,707 – Compounds which are useful for prevention and treatment of central nervous system disorders
5,726,316 – Pharmaceutical compositions for prevention and treatment of central nervous system disorders
Field of Use
Ispronicline (TC-1734). Ispronicline is a novel small molecule that we are developing as an oral treatment for conditions marked by cognitive impairment that afflict elderly persons, including Alzheimer’s disease and age associated memory impairment, commonly referred to as AAMI
Field of use is for nicotinic compounds for use in therapeutic applications, including for prevention and treatment of central nervous system disorders.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
